Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
The experiences of a seven-year study on deprenyl in the treatment of Parkinson's disease are summarized. It was found that the main advantage of deprenyl was that it permitted the reduction of the dose of levodopa in optimally treated patients. In the initial stage of Parkinson's disease deprenyl is only partially sufficient as monotherapy. Deprenyl can administered successfully for correcting the "wearing off" effect.
D000368:Aged; D001545:Benserazide / Q000627:therapeutic use; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*
D004338:Drug Combinations; D010627:Phenethylamines; C005177:benserazide, levodopa drug combination; D012642:Selegiline; D007980:Levodopa; D001545:Benserazide